济南前列腺的一般症状济南阴囊湿疹用什么药治疗效果好?,济南哪一种中药治疗早泄,济南一般割包皮多久能好,济南阴茎龟头[已删除],济南早泄应该要怎样治疗,济南哪些中药可以治疗早泄,济南手淫多了射精快了怎么治

The United States Secret Service said on Monday that following an investigation that closed several streets near the White House due to a suspicious package left in the area of Pennsylvania Avenue and Lafayette Park, the package was deemed "safe."The Secret Service said at 5:40 p.m. ET that H Street NW between 15th and 17th, Pennsylvania Ave between 15th and 17th, and the White house North Fence Line are closed.By 6:10 p.m., the Secret Service allowed streets near the White House to reopen after deeming the package as safe. 592

The RV industry, like every other sector of the travel industry, took a hit in business at the start of the coronavirus pandemic.“April was down about 30 to 35%,” said Jim Bracking.Bracking is the manager of the Loveland RV Resort in Colorado.“For every reservation we were gettingm we were getting a couple of cancellations,” Bracking added.However, about a month after a slew of cancellations came in, things have started to pick up significantly.“Reservations are up quite a bit,” said Bracking. “If you have been in the office, you could see the reservation clerks are very busy.”Vacationers started rebooking road trips as soon as Colorado and other states started to reopen.“You just got to get some form of normalcy back and yet be safe. This is one of the only ways we know how to do it,” said Suzie Limppo, who is vacationing in an RV at Loveland RV Resort.RV resorts, RV parks, and RV rentals are seeing a bounce back across the country.“We are now up over 1,000 percent from where we were in April,” said Jon Gray with RVshare.RVshare rents RV to vacationers and it’s just one RV rental company that has seen dramatic increases in rentals.“There is a premium on keeping your distance. There’s a premium on driving to where you want to go instead of flying, because people are afraid to get on airplanes right now,” said Gray. “So, we thought those things benefitted our business, but we didn’t realize it benefitted it as much as it has. It has been truly amazing.”The RV industry is one of the only sectors of travel and leisure seeing such a strong rebound, and until the threat of COVID-19 is behind us, industry experts expect continued high demand.“It is clear that this summer is a moment for the RV industry, for drive-to travel and for people kind of experiencing travel in a different way,” said Gray.Because of high demand, RV rental companies and resorts warn those interested in taking road trips and camping should book soon.“If somebody want to go camping, they should book their reservations now,” said Bracking. “For this year and even next year, because they are filing up and I suspect by July 4 they are going to be very full.” 2165

The smoke from dozens of wildfires in the western United States is stretching clear across the country — and even pushing into Mexico, Canada and Europe. While the dangerous plumes are forcing people inside along the West Coast, residents thousands of miles away in the East are seeing unusually hazy skies and remarkable sunsets.The wildfires racing across tinder-dry landscape in California, Idaho, Oregon and Washington are extraordinary, but the long reach of their smoke isn’t unprecedented. While there are only small pockets in the southeastern U.S. that are haze free, experts say the smoke poses less of a health concern for those who are farther away.The sun was transformed into a perfect orange orb as it set over New York City on Tuesday. Photographs of it sinking behind the skyline and glinting through tree leaves flooded social media. On Wednesday, New Jersey residents described a yellow tinge to the overcast skies, and weather forecasters were kept busy explaining the phenomenon and making predictions as to how long the conditions would last.On the opposite coast, air quality conditions were among some of the worst ever recorded. Smoke cloaked the Golden Gate Bridge and left Portland and Seattle in an ashy fog, as crews have exhausted themselves trying to keep the flames from consuming more homes and even wider swaths of forest.Satellite images showed that smoke from the wildfires has traveled almost 5,000 miles (8,000 kilometers) to Britain and other parts of northern Europe, scientists said Wednesday.The current weather system, which favors a westerly wind across the higher levels of the atmosphere, is to blame for the reach of the smoke, experts explained.“We always seem, at times, to get the right combination of enough smoke and the upper level jet stream to line up to bring that across the country, so we’re just seeing this again,” said Matt Solum with the National Weather Service’s regional operations center in Salt Lake City, Utah. “It’s definitely not the first time this has happened.”There could be some easing of the haze this weekend as a storm system is expected to move into the Pacific Northwest and could affect the conditions that helped the smoke travel across the country. But Solum said there’s always a chance for more smoke and haze to shift around.“Just due to all the wildfires that are going on, this is likely going to continue for a while,” he said. “You might have ebbs and flows of that smoke just depending on how the upper level winds set up.”Kim Knowlton, a senior scientist with the Natural Resources Defense Council in New York City, said she woke up Wednesday to a red sunrise and more haze.She said millions of people who live beyond the flames can end up dealing with diminished air quality as it’s not uncommon for wildfire smoke to travel hundreds of miles.Although the health impacts are reduced the farther and higher into the atmosphere the smoke travels, Knowlton and her colleagues said the resulting haze can exacerbate existing problems like asthma and add to ozone pollution. 3070

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Supreme Court on Tuesday rejected a challenge to a controversial Arkansas abortion law blocking medication-induced abortions.The law, passed in 2015, says that any physician who "gives, sells, dispenses, administers, or otherwise provides or proscribes the abortion-inducing drug" shall have to have a contract with a physician who has admitting privileges at a nearby hospital.The order, issued without comment, clears the way for the law to go into effect in mid-July if no other legal action is taken. Planned Parenthood is expected to make another challenge to the law in US district court."The Arkansas restriction, which was enacted supposedly to protect women's health, is medically unnecessary," lawyers for Planned Parenthood argued in court papers. They say it is unconstitutional because it places an undue burden on a patient's right to choose abortion.Medication abortion — available only early in a pregnancy — involves the combination of two pills called mifepristone and misoprostol.Lawyers for Arkansas say the law is a "commonsense requirement" that "merely requires medication abortion providers to have a contractual relationship (to ensure follow-up treatment if needed) with a physician that has admitting privileges.The-CNN-Wire 1263